Health, Vaccines, Lyme Disease, FDA, Medicine.
increase the number of enrollees for the phase 4 (aftermarket) safety trials. However, those results never came to light: with class-action lawsuits emerging from patients and dwindling market interest, LYMErix was removed from the market in 2002. And with market prospects dim, manufacturer Pasteur